Abstract: A method and system for detecting and treating a clot are disclosed. The method of detecting composition of a clot in a vessel of a patient may include introducing a solution containing tagged tissue plasminogen activator (tPA) into a circulatory system of the patient, waiting a predetermined time for the tagged tPA to interact with the clot, scanning an area of the patient corresponding to the clot, and outputting a composition of the clot based on an intensity of a signal at the clot in the scan corresponding to the tagged tPA.

Abstract: An aspiration catheter for assisting in the retrieval of a clot from a vessel of a patient including at least one electrode pair and a first pressure sensor positioned within an inner lumen of the aspiration catheter and a second and third pressure sensor positioned on an exterior surface of the aspiration catheter. The electrode pair and pressure sensors are in electrical communication with a control console. The control console is configured to modulate an aspiration vacuum pressure waveform pattern applied through the aspiration catheter based on electrical and pressure inputs from the one or more sensors, and optionally based on a blood pressure waveform pattern of the patient.

Abstract: Methods and systems for using a clot retrieval device for treating a clot in a blood vessel for use in the treatment of ischemic stroke to achieve a clinically effective revascularization or perfusion rate. Perfusion is restored to the blood vessel by passing the clot retrieval device by, through, or about the thrombus and removing the revascularization device to achieve, on the first pass, approximately a 63.2% final revascularization rate under the modified treatment in cerebral infarction score of equal to or greater than a grade of 2b (mTICI ?2b) for the plurality of human patients with one or more cerebral occlusions within a predetermined time period of natural stroke symptom onset.

Abstract: Example systems and methods of treatment are presented herein which generally involve expanding a bracing frame within a blood vessel between a clot and an aspiration catheter, aspirating the clot through a passageway of the bracing frame, and supporting the blood vessel by the bracing frame as negative pressure is created by the aspiration. The bracing frame can thereby reduce likelihood of blood vessel collapse compared to a similar procedure which does not include the bracing frame. The bracing frame can be removed from the blood vessel during treatment. In some examples, the bracing frame can further function to expand a mouth of the catheter. In some examples, the system can include a stentriever.

Abstract: A device and method for establishing retrograde blood flow during recanalization of a vessel having a targeted blockage. While in a collapsed state an occluding component is introduced distally intravascularly traversing the targeted blockage to its distal side. Then, the occluding component transitions to an expanded state having an enlarged diameter forming a seal with an internal wall of the vessel prohibiting anterograde blood flow beyond the expanded occluding component. Retrograde blood flow is thereby established in a region of the vessel bound at one end by the occluding component and at an opposite end by the targeted blockage by dispensing a flushing fluid into the region of the vessel.

Abstract: A device and method for establishing retrograde blood flow during recanalization of a vessel having a targeted blockage. While in a collapsed state an occluding component is introduced distally intravascularly traversing the targeted blockage to its distal side. Then, the occluding component transitions to an expanded state having an enlarged diameter forming a seal with an internal wall of the vessel prohibiting anterograde blood flow beyond the expanded occluding component. Retrograde blood flow is thereby established in a region of the vessel bound at one end by the occluding component and at an opposite end by the targeted blockage by dispensing a flushing fluid into the region of the vessel.

Abstract: A method or use for managing one or more acute ischemic events. The method can include determining criteria of a clot; classifying the clot based on the criteria and generating a classification; determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using aspiration, restoring perfusion using a first reperfusion device, and/or restoring perfusion using a second reperfusion device; and treating the clot based on the individualized treatment protocol.

Abstract: A device and method for establishing retrograde blood flow during recanalization of a vessel having a targeted blockage. While in a collapsed state an occluding component is introduced distally intravascularly traversing the targeted blockage to its distal side. Then, the occluding component transitions to an expanded state having an enlarged diameter forming a seal with an internal wall of the vessel prohibiting anterograde blood flow beyond the expanded occluding component. Retrograde blood flow is thereby established in a region of the vessel bound at one end by the occluding component and at an opposite end by the targeted blockage by dispensing a flushing fluid into the region of the vessel.

Abstract: A tissue modification apparatus includes at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue. The plurality of grippers are each secured to a first force actuator. The first plurality of grippers are each adapted to pivot relative to the first force actuator about an axis perpendicular to the plane. In some cases, a plurality of grippers are attached to a force actuator by a passive force transfer mechanism. In some cases, individual force actuators are attached by pivoted connections to individual grippers. Methods of treating tissue can secure tensioned tissue to a frame to retain the tension during a treatment (e.g., cross-linking the tissue with a chemical cross-linker).

Abstract: A tissue modification apparatus includes at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue. The plurality of grippers are each secured to a first force actuator. The first plurality of grippers are each adapted to pivot relative to the first force actuator about an axis perpendicular to the plane. In some cases, a plurality of grippers are attached to a force actuator by a passive force transfer mechanism. In some cases, individual force actuators are attached by pivoted connections to individual grippers. Methods of treating tissue can secure tensioned tissue to a frame to retain the tension during a treatment (e.g., cross-linking the tissue with a chemical cross-linker).

Abstract: A method of treating pericardial tissue that includes contacting at least a portion of a pericardial sac with a chemical while the pericardial sac is tensioned by an application of fluid pressure to an inside face of the pericardial sac.

Abstract: A tissue modification apparatus includes at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue. The plurality of grippers are each secured to a first force actuator. The first plurality of grippers are each adapted to pivot relative to the first force actuator about an axis perpendicular to the plane. In some cases, a plurality of grippers are attached to a force actuator by a passive force transfer mechanism. In some cases, individual force actuators are attached by pivoted connections to individual grippers. Methods of treating tissue can secure tensioned tissue to a frame to retain the tension during a treatment (e.g., cross-linking the tissue with a chemical cross-linker).

Abstract: A tissue modification apparatus includes at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue. The plurality of grippers are each secured to a first force actuator. The first plurality of grippers are each adapted to pivot relative to the first force actuator about an axis perpendicular to the plane. In some cases, a plurality of grippers are attached to a force actuator by a passive force transfer mechanism. In some cases, individual force actuators are attached by pivoted connections to individual grippers. Methods of treating tissue can secure tensioned tissue to a frame to retain the tension during a treatment (e.g., cross-linking the tissue with a chemical cross-linker).

Abstract: A method of treating pericardial tissue that includes contacting at least a portion of a pericardial sac with a chemical while the pericardial sac is tensioned by an application of fluid pressure to an inside face of the pericardial sac.

Abstract: This document relates to tissue modification and, more particularly, to modification of biological tissue for implantation in a mammal. For example, this document relates to tissue tensioning devices and methods used during fixation of tissues for bioprosthetic heart valves.

Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, methods of using the same, processes for preparing the same, and intermediates thereof.

Abstract: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.

Abstract: The present invention provides BACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation.

Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, methods of using the same, processes for preparing the same, and intermediates thereof.

Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.